CHENGDU, China I June 5, 2025 I On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced ...

PLAINSBORO, NJ, USA I June 6, 2025 I Novo Nordisk today announced that new hemophilia data will be presented at the upcoming International Society on ...

STOCKHOLM, Sweden I June 6, 2025 I Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 ...

TAIPEI, Taiwan I June 06, 2025 I OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies ...

Data show SPR301 lowered α-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with favorable safety ...

LONDON, UK I June 02, 2025 I GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review the NDA for ...

Figure 1. DAZALS exploratory overall survival analysis at one-year – patients who received 300 mg of dazucorilant compared to ...

Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest data CHICAGO, IL, USA I June 05, 2025 I MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the ...

Company enters into option agreement with NeurOp to in-license novel GluN2B antagonists – Compounds include a highly potent and selective Phase 1-complete candidate and seven preclinical candidates – ...

SAN DIEGO, CA, USA I June 05, 2025 I Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology ...

LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes.

ROCKVILLE, MD, USA I June 5, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase ...